GH Research (GHRS) Other Non-Current Assets (2025 - 2026)
GH Research (GHRS) posted quarterly Other Non-Current Assets of $1.6 million for Q4 2025, up 40.62% quarter-over-quarter from $1.2 million in Q3 2025.
Powered by 
Analysis
GH Research (GHRS) Other Non-Current Assets (2025 - 2026) Analysis & Trends
GH Research's Other Non-Current Assets history runs 1 years deep, the most recent figure standing at $1.6 million for Q4 2025.
- In Q4 2025, Other Non-Current Assets changed N/A year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $1.6 million (changed N/A YoY), while the FY2025 annual figure was $1.6 million, changed N/A from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $1.6 million, up from $1.2 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $1.7 million in Q2 2025, with the low at $1.1 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 618.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 42.45 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 109.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 65.13 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 62.96 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 104.44 Mn |
| 10 | GH Research | 1.72 Bn | 1.36 Bn | - | 3.02 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 3.02 Mn |
| Mar 31, 2026 | 2.46 Mn |
| Dec 31, 2025 | 1.63 Mn |
| Sep 30, 2025 | 1.16 Mn |
| Jun 30, 2025 | 1.66 Mn |
| Mar 31, 2025 | 1.09 Mn |